17 September 2020 
EMA/CHMP/471522/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Fycompa 
perampanel 
On 17 September 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Fycompa. The marketing authorisation holder for this medicinal product is Eisai GmbH. 
The CHMP adopted an extension to the existing indication as follows:2 
Fycompa (perampanel) is indicated for the adjunctive treatment of  
- 
- 
partial-onset seizures (POS) with or without secondarily generalised seizures in 
patients from 4 years of age and older. 
primary generalised tonic-clonic (PGTC) seizures in patients from 7 years of age 
and older with idiopathic generalised epilepsy (IGE). 
Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without 
secondarily generalised seizures in adult and adolescent patients from 12 years of age with 
epilepsy. 
Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in 
adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy (see 
section 5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
 
 
 
 
 
